Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty

This article was originally published in The Pink Sheet Daily

Executive Summary

Discontinuation is unrelated to prior safety suspension, say Amylin and Takeda, who acknowledge that "this is a difficult time for innovators and regulators."

Related Content

FDA Goes To Committee With Uncertainty About Metreleptin Efficacy For Partial Lipodystrophy
Repurposing Leptin: How a “Fat Drug” Became a Model for a Leaner Industry
Senate Wants FDA Plan To Speed Obesity Drug Development
Senate Wants FDA Plan To Speed Obesity Drug Development
Obesity Drug Developers Go With The Gut: R&D Hopes Focus On Locally Acting Agents
Late-Stage Obesity Pipeline Is Stuffed With Mix Of Mechanisms
More Obesity Setbacks For Amylin And Takeda
Amylin And Takeda Team Up In Obesity





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts